Gene: SGCB
Official Full Name: sarcoglycan betaprovided by HGNC
Gene Summary: This gene encodes a member of the sarcoglycan family. Sarcoglycans are transmembrane components in the dystrophin-glycoprotein complex which help stabilize the muscle fiber membranes and link the muscle cytoskeleton to the extracellular matrix. Mutations in this gene have been associated with limb-girdle muscular dystrophy.[provided by RefSeq, Oct 2008]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO35461 | SGCB Knockout cell line (HeLa) | Human | SGCB | 1:3~1:6 | Negative | Online Inquiry |
KO35462 | SGCB Knockout cell line (HCT 116) | Human | SGCB | 1:2~1:4 | Negative | Online Inquiry |
KO35463 | SGCB Knockout cell line (HEK293) | Human | SGCB | 1:3~1:6 | Negative | Online Inquiry |
KO35464 | SGCB Knockout cell line (A549) | Human | SGCB | 1:3~1:4 | Negative | Online Inquiry |
SGCB Gene Knockout Cell Lines are specialized cellular models engineered to lack the expression of the SGCB gene, which encodes for the beta subunit of the dystrophin-glycoprotein complex. These cell lines serve as critical tools for researchers studying the pathophysiology of muscular dystrophies, particularly those related to dystrophin deficiencies. By eliminating SGCB expression, these models facilitate the investigation of downstream effects on muscle cell function, signaling pathways, and interaction with the extracellular matrix.
The primary mechanism of action involves targeted gene editing, employing advanced CRISPR/Cas9 technology, which ensures precise deletion of the SGCB gene. This knockout effectively mimics the genetic conditions seen in various myopathies, allowing researchers to explore how the loss of SGCB contributes to muscle degeneration and the potential for therapeutic interventions. This capability positions the SGCB Gene Knockout Cell Lines as invaluable assets for drug discovery, gene therapy research, and the study of muscular dystrophy mechanisms.
The scientific significance of these cell lines extends to both academic and clinical applications, including the development of novel treatment strategies and the validation of therapeutic compounds aimed at restoring muscle function. Compared to traditional cell models that may not accurately represent the disease state, these knockouts provide a more relevant physiological context.
Distinct advantages of the SGCB Gene Knockout Cell Lines include their robust consistency, reproducibility, and compatibility with various assays, making them ideal for high-throughput screening and detailed mechanistic studies. Furthermore, they present a unique opportunity for researchers aiming to develop personalized medicine approaches in the treatment of muscular dystrophies by providing a clear model for understanding genetic variability.
With a commitment to advancing scientific research, our company specializes in creating high-quality biological products that meet the needs of researchers and clinicians alike. We take pride in our extensive expertise and dedication to supporting innovative solutions in the field of molecular and cell biology.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.